Biocon has signed a 10-year supply contract with Bahiafarma and Bionovis for Pertuzumab in Brazil. This partnership aims to advance the production and commercialization of the HER2-positive breast cancer therapy under Brazil’s Productive Development Partnership (PDP) program. Biocon will receive milestone payments and a share of revenues, with phased localization planned in Brazil.
Biocon Expands Global Reach with Brazilian Partnership
Biocon Limited, a global biopharmaceutical company, announced today the signing of a significant 10-year supply agreement with Bahiafarma and Bionovis for Pertuzumab in Brazil. This strategic move marks a crucial milestone in advancing the production and commercialization of the HER2-positive breast cancer therapy within the country’s Productive Development Partnership (PDP) program.
Key Contract Details and Market Access
The consortium, comprising Biocon, Bahiafarma, and Bionovis, has secured 100% allocation under Brazil’s decade-long PDP program for Pertuzumab. This agreement grants the consortium exclusive access to Brazil’s public healthcare market, which represents approximately 70% of the country’s demand for Pertuzumab. The partnership is expected to facilitate the long-term adoption of Biocon’s product within Brazil’s public oncology network.
Financial Implications and Localization
Under the terms of the agreement, Biocon is set to receive milestone payments and a share of the revenues generated from the Brazil PDP opportunity over the 10-year period. A key aspect of the PDP framework includes the phased localization of the product in Brazil over the mid to long term, fostering local manufacturing capabilities.
Strategic Importance and Leadership Statements
Shreehas Tambe, CEO & Managing Director of Biocon, highlighted the significance of Brazil as an important market and emphasized the potential of strong partnerships in building local capabilities and expanding access to affordable medicines. He stated, “This long-term supply contract for Pertuzumab marks a significant milestone in this journey, enabling us to reach more patients living with HER2-positive breast cancer and address an important healthcare need at scale.”
Ceuci Nunes, CEO of Bahiafarma, expressed optimism about advancing a strategic public health project, noting the collaboration’s role in incorporating complex technology and strengthening Brazil’s capacity to produce essential medicines. Odnir Finotti, CEO of Bionovis, reiterated the commitment to public policies and Productive Development Partnerships, aiming to expand access to complex biological medicines and promote national productive autonomy.
About Pertuzumab and Brazilian Partners
Pertuzumab is a monoclonal antibody vital for treating HER2-positive breast cancer. Currently, it is not manufactured locally in Brazil and represents a significant expenditure for the country’s Unified Health System (SUS). Bahiafarma is a public pharmaceutical laboratory focused on research, development, and production of medicines for Brazil’s SUS. Bionovis is a Brazilian biotechnology company specializing in the development, manufacturing, and commercialization of complex biological medicines and biosimilars.
Source: BSE
